Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy. - Wikidata - awgldk - TriplyDB

Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.

Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.

http://www.wikidata.org/entity/Q37101977

about

Trial Watch:: Oncolytic viruses for cancer therapy Trial Watch-Oncolytic viruses and cancer therapy A novel oncolytic adenovirus based on simian adenovirus serotype 24 Development of novel vaccine vectors: Chimpanzee adenoviral vectors.

P2860

Q27021951-328EE1AD-08EC-4FE2-8A20-22CAA399DC80 Q28072347-1F0737ED-A976-4448-8B58-302660A068CE Q33688856-5241EC0E-4462-452E-A97E-BFFBB2B6D2F5 Q47558190-26795188-90B4-4BEC-939D-CCA4CB490CD0

P2860

Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.

http://www.wikidata.org/entity/Q37101977

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Tat-PTD-modified oncolytic ade ...... cer for neuroblastoma therapy.

@en

Tat-PTD-modified oncolytic ade ...... cer for neuroblastoma therapy.

@nl

type

label

Tat-PTD-modified oncolytic ade ...... cer for neuroblastoma therapy.

@en

Tat-PTD-modified oncolytic ade ...... cer for neuroblastoma therapy.

@nl

prefLabel

Tat-PTD-modified oncolytic ade ...... cer for neuroblastoma therapy.

@en

Tat-PTD-modified oncolytic ade ...... cer for neuroblastoma therapy.

@nl

P1433

Q37101977-AA3A5AC8-0810-43CD-8859-E3037FDA0FD9

P1476

Q37101977-DF7F1F81-D17D-4BAD-BF01-A879868AEEDB

P2093

Q37101977-15E6AC55-83DC-4617-BCF4-6F7AFB361D32

Q37101977-5B7A783B-4F9C-452A-B1BD-A9CDD629CF67

Q37101977-6382060B-87B0-4F23-AD0C-3CC0827643F4

Q37101977-76F54E0B-A6D0-4E0B-A0ED-717F6C6BEC61

Q37101977-C7CAEED9-A475-4AE1-8135-76E34D98354E

Q37101977-DE94AE70-9AC5-4B4A-90D4-76D7DB3643E5

P2860

Q37101977-14F2B2B8-D043-4471-AFF6-4128C63F3F06

Q37101977-1CA9CA2A-CD4C-44B8-9E10-A94F3924FF79

Q37101977-27BB92BE-95D0-498D-B751-6C1303A5B953

Q37101977-2B8376B7-E986-45BF-9760-5849603C5E9C

Q37101977-3A346B39-6AFA-4A24-9CA6-E4F6E35FD477

Q37101977-3C106BFA-CE84-46B4-BE70-DD810123C644

Q37101977-41E57CFD-4A9D-463C-830E-4992E33F7646

Q37101977-6E08337D-C596-4A17-AD7F-FCB1B11F1986

Q37101977-70A8B7F3-AAA9-4037-A398-15E276EA5B4E

Q37101977-76A68034-2761-4127-A8B0-360D1D08CBAA

P304

Q37101977-00116260-C4A6-4030-AB73-861C05787B71

P31

Q37101977-01E10D94-9AFE-4BA4-9057-4A1171220CE1

P356

Q37101977-4F762D1B-1260-40BB-9D7B-418BB18CE799

P433

Q37101977-444D8B62-1C66-4360-8131-B16C6AEA05DB

P478

Q37101977-40F291C0-E64C-466D-855A-C38F2A15F272

P577

Q37101977-E1380E69-9666-4519-9FC3-9801791A43E5

P5875

Q37101977-CA4D0458-39EB-4D7D-93C7-F59B1DCA18B5

P698

Q37101977-4E7607F6-6D02-4DBA-86BB-48F7B57E3775

P921

Q37101977-77A9E333-9882-4392-B87B-972E3F947C74

Q37101977-F7986E13-1DBB-48F2-8E26-FA54503D90C7

P932

Q37101977-0CE224E9-7B2B-4D78-B2C3-77B7082FE077

P356

P1433

Human Gene Therapy

P1476

Tat-PTD-modified oncolytic ade ...... cer for neuroblastoma therapy.

@en

P2093

Berith Nilsson

http://www.w3.org/2001/XMLSchema#string

Chuan Jin

http://www.w3.org/2001/XMLSchema#string

Di Yu

http://www.w3.org/2001/XMLSchema#string

Justyna Leja

http://www.w3.org/2001/XMLSchema#string

Magnus Essand

http://www.w3.org/2001/XMLSchema#string

Matko Čančer

http://www.w3.org/2001/XMLSchema#string

P2860

A simplified system for generating recombinant adenoviruses

Tissue-specific expression of human achaete-scute homologue-1 in neuroendocrine tumors: transcriptional regulation by dual inhibitory regions

Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability.

Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?

Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer.

Cloning and characterization of a novel human secretory protein: secretogranin III.

The granin family--its role in sorting and secretory granule formation.

Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures.

Secretogranin II: a key AP-1-regulated protein that mediates neuronal differentiation and protection from nitric oxide-induced apoptosis of neuroblastoma cells.

Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors

P304

766-775

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/HUM.2012.132

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

253331594

http://www.w3.org/2001/XMLSchema#string

P698

23889332

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

3746216

http://www.w3.org/2001/XMLSchema#string